SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Surging Treasury yields and a global bond selloff are fueling concern that higher borrowing costs and possible Fed hikes could pressure equities. Traders are divided between bearish warnings about a broader selloff and bulls viewing sharp rebounds as buying opportunities, with cooler inflation and strong Micron results cited as counterpoints.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A global bond selloff and rising Treasury yields are fueling concern about pressure on QQQs growth-heavy holdings, even as the index repeatedly rebounds. Traders are divided over whether AI and semiconductor strength, including optimism after Microns report, can sustain the rally or whether higher rates and broader macro risks will weigh on it.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns blowout results and stronger outlook, driven by AI-related memory demand and tight supply, are drawing attention, but the stocks muted reaction has surprised many traders. Bulls see the outlook and continued supply constraints as support for further growth, while skeptics point to high expectations, rising capex, Treasury yields and memory-cycle risks; options traders also lament the flat move and volatility decay.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under pressure as long-term Treasury yields reach multi-decade highs, with traders pointing to persistent inflation concerns, strong growth, and government debt as reasons yields may stay elevated. The discussion is largely bearish on the ETFs continued selloff, though some traders see oversold conditions and are accumulating in anticipation of a rebound.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nikes upcoming fiscal Q1 earnings have traders focused on whether results and guidance can show progress in the turnaround, as the shares trade near multiyear lows. The community is split between bearish views citing weak demand, China and competition, and contrarian bets on a recovery or short squeeze amid elevated short interest.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention after Panasonic Advanced Technology, Jasmy and JANCTION described a working Smart Render product using distributed GPUs, with plans for commercial use. Traders welcomed the tangible development, while some questioned whether it will create direct demand for JASMY or translate into adoption amid concerns about exchange delistings.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Googles Gemini 4 Argon launch, focused on coding and cybersecurity, is driving attention as traders debate whether it can bolster Alphabets position in the AI race. Enthusiasm over the models capabilities is tempered by complaints that the stocks initial gains faded and by broader concerns about competition from Meta and other AI developers.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Rising Treasury yields and persistent rate-hike concerns are weighing on the rate-sensitive small-cap Russell 2000, which traders say is underperforming large-cap tech as borrowing and refinancing costs pressure smaller companies. The community is divided between bearish calls for further weakness and hopes for an oversold bounce near the 200-day moving average, with some pointing to cooler PCE data as potential relief.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

FDA acceptance of Intellias Lonvo-z application for hereditary angioedema with priority review and a March 2027 decision date is the main focus. Traders view it as an important step toward commercialization, while debating the muted share reaction and concerns about financing, cash burn, and launch execution.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentums strong results, upbeat outlook and comments about rising AI-optics orders are reinforcing the view that it benefits from growing data-center connectivity demand. Traders remain divided between the growth story and concerns about its rich valuation, with sharp swings prompting both breakout bets and profit-taking or short positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Notable Thursday Option Activity: SVRA, CAR, SPCX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Savara Inc (Symbol: SVRA), where a total of 10,285 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 70.6% of...

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new...

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. While we have regulatory applications under review across the U.S., EU...

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human...

Here's Why You Should Add Savara Stock to Your Portfolio Now

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new...

Savara Announces Chief Financial and Administrative Officer Transition

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of...

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.16	--	--	N/A
Q2 '26	-$0.14	-$0.16	-12.28%	MISSED
Q1 '26	-$0.14	-$0.15	-11.11%	MISSED
Q4 '25	-$0.12	-$0.13	-10.64%	MISSED
Q3 '25	-$0.13	-$0.14	-5.66%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

SVRA Earnings

Upcoming Earnings: Q3 '26

Historical Earnings